Position in ABBV
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$471,572
+$65,775 QoQ
Shares Held
1,874
+5.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
#3,222
of 4,153 holders
Holding Since
Mar 2022
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026JACKSON THORNTON WEALTH MANAGEMENT, LLC holds $7,595,597 across 8 Drug Manufacturers - General names. ABBV ranks #5 (6.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,766 | $2,118,192 | |
| 2 | MRK |
Merck & Co., Inc.
|
12,006 | $1,542,771 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
21,395 | $1,232,779 | |
| 4 | JNJ |
Johnson & Johnson
|
4,351 | $1,105,023 | |
| 5 | ABBV |
AbbVie Inc.
This page
|
1,874 | $471,572 | |
| 6 | BIIB |
Biogen Inc.
|
1,829 | $395,173 | |
| 7 | PFE |
Pfizer Inc
|
15,962 | $384,364 | |
| 8 | NVS |
Novartis AG
|
2,206 | $345,723 |
All Filings in ABBV
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $471,572 | 1,874 | Shares | Other | 2026-08-06 | |
| 2025-12-31 | $405,797 | 1,776 | Shares | Other | 2026-01-22 | |
| 2025-09-30 | $342,447 | 1,479 | Shares | Other | 2025-10-29 | |
| 2025-06-30 | $270,076 | 1,455 | Shares | Other | 2025-07-30 | |
| 2025-03-31 | $287,670 | 1,373 | Shares | Sole | 2025-04-29 | |
| 2024-12-31 | $213,239 | 1,200 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $236,580 | 1,198 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $206,167 | 1,202 | Shares | Other | 2024-11-07 | |
| 2024-03-31 | $224,165 | 1,231 | Shares | Other | 2024-05-15 | |
| 2022-06-30 | $221,469 | 1,446 | Shares | Sole | 2022-08-02 | |
| 2022-03-31 | $203,285 | 1,254 | Shares | Sole | 2022-05-12 | |
| No filing history on record for this holder in this stock. | ||||||